2027 Co-Op, Safety Epidemiology
Moderna
Summary
Our Spring/Summer Co-op Program runs from January 18, 2027 through June 25, 2027. All applicants must be available for the full duration of the program. We are seeking a highly motivated PhD/ScD student to join our Global Safety Epidemiology program, providing a unique opportunity to gain hands-on experience in real-world epidemiologic research, safety monitoring, signal evaluation, and integrated evidence planning in a regulated biopharmaceutical environment.
Job description
Here's What You'll Do
- Gain exposure to the role of Epidemiology in pharmacovigilance across the development lifecycle.
- Conduct epidemiologic research to contextualize and evaluate safety signals, important potential risks, and special populations relevant to safety monitoring (e.g., pregnant women).
- Contribute to evidence generation and synthesis for vaccine safety monitoring in key global markets outside the US.
- Engage with cross-functional teams, including Clinical Safety and Pharmacovigilance, Real-World Evidence Analytics, Medical Affairs, Health Economics & Outcomes Research, and Clinical Development.
- Contribute to cross functional signal detection, validation, and evaluation workflows.
- Lead and present findings from an epidemiologic project addressing a topic relevant to safety monitoring (e.g., characterizing incidence of one or more safety topics of interest).
Here's What You'll Need (Minimum Qualifications)
- Currently enrolled in a PhD or ScD program in Epidemiology or a closely related discipline.
- Strong background in epidemiology, biostatistics.
- Experience with SAS or R.
Here's What You'll Bring to the Table (Preferred Qualifications)
- Interest in vaccine development, pharmacoepidemiologic methods, pharmacovigilance, and data-driven decision-making.
- Ability to meet deadlines, team-oriented mindset, adaptability under pressure, and a proactive approach to problem-solving.
- Demonstrated ability to work independently while contributing effectively within a team environment.
- Strong written and verbal communication skills.
- High attention to detail and commitment to quality and compliance.
- A desire to make an impact as part of a high-growth, transformational company that is Bold, Relentless, Curious, and Collaborative.
Requirements
- Currently enrolled in a PhD or ScD program in Epidemiology or a closely related discipline
- Strong background in epidemiology
- Strong background in biostatistics
- Experience with SAS or R
- Must hold work authorization in US without need for future sponsorship
- Available for full duration of program (January 18, 2027 - June 25, 2027)
Benefits
- Meditation and mindfulness classes
- Subsidized commuter benefits
- Paid time off
- Vacation
- Sick time
- Holidays
- Volunteer days
- Discretionary year-end shutdown
Company overview
Moderna, Inc. is a pioneering American biotechnology and pharmaceutical company headquartered in Cambridge, Massachusetts, that has revolutionized the field of medicine through its groundbreaking messenger RNA (mRNA) technology. Founded in 2010, the company has established itself as a global leader in RNA therapeutics, primarily focusing on mRNA vaccines and treatments. Moderna's innovative platform uses mRNA to provide cellular instructions for producing proteins that trigger immune responses, creating a new category of medicines with significant potential to improve patient outcomes across various therapeutic areas. The company gained worldwide recognition during the COVID-19 pandemic for developing one of the earliest and most effective mRNA vaccines, which demonstrated the transformative potential of its technology platform. Beyond infectious diseases, Moderna is advancing a diverse pipeline of 44 treatment and vaccine candidates across infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune conditions. With approximately 5,800 employees and a strong commitment to scientific innovation, Moderna continues to expand its manufacturing capabilities and research initiatives to deliver the greatest possible impact through mRNA medicines.